Brief: Context Therapeutics Reports Preliminary Phase 2 Data For ONA-XR In Metastatic Breast Cancer
08/12/2022 13:36
Dec 8 (Reuters) - Context Therapeutics Inc CNTX.O :
* CONTEXT THERAPEUTICS® REPORTS ENCOURAGING PRELIMINARY
PHASE 2
DATA FOR ONA-XR IN METASTATIC BREAST CANCER
* CONTEXT THERAPEUTICS - DATA DEMONSTRATE PRELIMINARY
4-MONTH PFS
RATE OF 44% IN ONGOING PHASE 2 TRIAL IN SECOND- OR THIRD-LINE
METASTATIC BREAST CANCER
* CONTEXT THERAPEUTICS - DATA FROM PHASE 1B PORTION OF TRIAL
IS
EXPECTED IN Q4 2023.
Source text for Eikon: ID:nGNX8gZLQW
Further company coverage: CNTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202